Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center
Articles
Rate and Class Effect of ILD with Antibody Drug Conjugates
Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center;Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center;Axel Grothey, MD, West Cancer Center, University of Tennessee;Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins;Tanios Bekaii-Saab, MD, FACP, Mayo Clinic
June 30th 2020Read More
Use of Antibody Drug Conjugates and Potential for ILD
Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center;Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center;Axel Grothey, MD, West Cancer Center, University of Tennessee;Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins;Tanios Bekaii-Saab, MD, FACP, Mayo Clinic
June 30th 2020Read More
Changes in Cancer Treatment and Management of ILD
Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center;Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center;Axel Grothey, MD, West Cancer Center, University of Tennessee;Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins;Tanios Bekaii-Saab, MD, FACP, Mayo Clinic
June 30th 2020Read More
Risks for Developing ILD and Personal Experience
Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center;Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center;Axel Grothey, MD, West Cancer Center, University of Tennessee;Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins;Tanios Bekaii-Saab, MD, FACP, Mayo Clinic
June 30th 2020Read More
Antibody Drug Conjugates and Interstitial Lung Disease Risk
Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center;Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center;Axel Grothey, MD, West Cancer Center, University of Tennessee;Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins;Tanios Bekaii-Saab, MD, FACP, Mayo Clinic
June 30th 2020Read More
Latest Updated Articles
Published: October 30th 2024 | Updated: November 7th 2024
Phase 1/2 ALKOVE-1 Study of NVL-655 in ALK-positive (ALK+) Solid Tumors
Published: October 18th 2024 | Updated: October 21st 2024
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Published: October 14th 2024 | Updated: October 16th 2024
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Published: September 27th 2024 | Updated: October 9th 2024
Petosemtamab Plus Pembrolizumab vs. Pembrolizumab Alone for First-Line (1L) Treatment of Recurrent/Metastatic (R/M) PD-L1–Positive Head and Neck Squamous Cell Carcinoma (HNSCC): A Randomized, Open-Label, Phase 3 Trial
Published: September 30th 2024 | Updated: October 4th 2024
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Published: September 27th 2024 | Updated: October 4th 2024
Real World Evidence of Treatment Practices and Therapeutic Outcomes for Newly Diagnosed NSCLC Patients With Non-Classical EGFR Mutations Demonstrates High Unmet Medical Need
